Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma
Abstract
The prognosis of patients affected by cholangiocarcinoma is classically poor. Until recently, chemotherapeutic drugs were the only systemic treatment option available, leading to an overall survival lower than 1 year. In recent decades, different genetic alterations have been identified as playing a key role in the oncogenic signaling. A subgroup of intrahepatic cholangiocarcinoma is characterized by FGFR family mutations, more frequently...
Paper Details
Title
Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma
Published Date
Feb 1, 2021
Journal
Volume
17
Issue
4
Pages
389 - 402
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History